These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20585260)

  • 1. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.
    Song I; Min SS; Borland J; Lou Y; Chen S; Ishibashi T; Wajima T; Piscitelli SC
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):365-7. PubMed ID: 20585260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
    German P; Warren D; West S; Hui J; Kearney BP
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
    Ramanathan S; Shen G; Cheng A; Kearney BP
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.
    Hu CY; Liu YM; Liu Y; Chen Q; Wang W; Wu K; Dong J; Li J; Jia JY; Lu C; Sun SX; Yu C; Li X
    Clin Ther; 2013 Dec; 35(12):1884-9. PubMed ID: 24148552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
    Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
    J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
    Kearney BP; Mathias A; Mittan A; Sayre J; Ebrahimi R; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):278-83. PubMed ID: 17079992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
    Hoetelmans RM; Mariën K; De Pauw M; Hill A; Peeters M; Sekar V; De Doncker P; Woodfall B; Lefebvre E
    Br J Clin Pharmacol; 2007 Nov; 64(5):655-61. PubMed ID: 17610528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
    Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
    Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R;
    AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
    Min S; Song I; Borland J; Chen S; Lou Y; Fujiwara T; Piscitelli SC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):254-8. PubMed ID: 19884365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination.
    Chittick GE; Zong J; Begley JA; Alianti JR; Sorbel JJ; Blum MR
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):627-36. PubMed ID: 19049696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.